肠道菌群与非酒精性脂肪性肝病的关系

肖丽; 杨玲

doi:10.3969/j.issn.1001-5256.2017.04.040

肠道菌群与非酒精性脂肪性肝病的关系

DOI: 10.3969/j.issn.1001-5256.2017.04.040

肖丽,
杨玲

华中科技大学同济医学院附属协和医院消化内科

基金项目:

国家自然科学基金资助(81370550,81570530)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2024
- HTML全文浏览量: 16
- PDF下载量: 443
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-09
- 出版日期: 2017-04-20

Gut microbiota and nonalcoholic fatty liver disease

Xiao Li,
Yang Ling

Department of Gastroenterology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是一种常见的多因素参与的肝脏疾病,其发病率在全球逐渐上升。近年来发现肠道菌群参与了NAFLD的发生发展,从肠道菌群的影响因素、肠道菌群及其代谢产物在NAFLD发生发展中的作用等方面,综述了肠道菌群与NAFLD的关系,指出针对肠道菌群及其代谢产物的干预策略可能是预防和治疗NAFLD的新靶点。
- 肠道菌群 /
- 脂肪肝 /
- 代谢 /
- 综述
Abstract: Nonalcoholic fatty liver disease ( NAFLD) is a common liver disease with multiple factors involved, and its incidence is gradually increasing around the world. Recent studies have found that gut microbiota is involved in the development and progression of NAFLD. This article summarizes the association between gut microbiota and NAFLD from the aspects of influencing factors for gut microbiota and the roles of gut microbiota and its metabolites in the development and progression of NAFLD and points out that the intervention of gut microbiota and its metabolites may be a new target for the prevention and treatment of NAFLD.
- gut microbiota /
- fatty liver /
- metabolism /
- review

HTML全文

参考文献(59)

[1]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[2]WONG RJ, AGUILAR M, CHEUNG R, et al.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States[J].Gastroenterology, 2015, 148 (3) :547-555.

[3]STEPANOVA M, RAFIQ N, YOUNOSSI ZM.Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease:a population-based study[J].Gut, 2010, 59 (10) :1410-1415.

[4]TILG H, MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis[J].Hepatology, 2010, 52 (5) :1836-1846.

[5]QIN J, LI R, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature, 2010, 464 (7285) :59-65.

[6]COSTELLO EK, LAUBER CL, HAMADY M, et al.Bacterial community variation in human body habitats across space and time[J].Science, 2009, 326 (5960) :1694-1697.

[7]COMPARE D, COCCOLI P, ROCCO A, et al.Gut-liver axis:the impact of gut microbiota on non alcoholic fatty liver disease[J].Nutr Metab Cardiovasc Dis, 2012, 22 (6) :471-476.

[8]DAVID LA, MAURICE CF, CARMODY RN, et al.Diet rapidly and reproducibly alters the human gut microbiome[J].Nature, 2014, 505 (7484) :559-563.

[9]de WIT N, DERRIEN M, BOSCH-VERMEULEN H, et al.Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine[J].Am J Physiol Gastrointest Liver Physiol, 2012, 303 (5) :g589-g599.

[10]MORO-SIBILOT L, BLANC P, TAILLARDET M, et al.Mouse and human liver contain immunoglobulin a-secreting cells originating from Peyer's patches and directed against intestinal antigens[J].Gastroenterology, 2016, 151 (2) :311-323.

[11]YAN AW, FOUTS DE, BRANDL J, et al.Enteric dysbiosis associated with a mouse model of alcoholic liver disease[J].Hepatology, 2011, 53 (1) :96-105.

[12]LLOPIS M, CASSARD AM, WRZOSEK L, et al.Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J].Gut, 2016, 65 (5) :830-839.

[13]CHEN Y, YANG F, LU H, et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology, 2011, 54 (2) :562-572.

[14]THIEMANN S, SMIT N, STROWIG T.Antibiotics and the intestinal microbiome:individual responses, resilience of the ecosystem, and the susceptibility to infections[J].Curr Top Microbiol Immunol, 2016, 398:123-146.

[15]COX LM, YAMANISHI S, SOHN J, et al.Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences[J].Cell, 2014, 158 (4) :705-721.

[16]SRINIVAS G, MOLLER S, WANG J, et al.Genome-wide mapping of gene-microbiota interactions in susceptibility to autoimmune skin blistering[J].Nat Commun, 2013, 4 (9) :2462.

[17]GOODRICH JK, WATERS JL, POOLE AC, et al.Human genetics shape the gut microbiome[J].Cell, 2014, 159 (4) :789-799.

[18]FOLSERAAS T, MELUM E, RAUSCH P, et al.Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci[J].J Hepatol, 2012, 57 (2) :366-375.

[19]KNIGHTS D, SILVERBERG MS, WEERSMA RK, et al.Complex host genetics influence the microbiome in inflammatory bowel disease[J].Genome Med, 2014, 6 (12) :107.

[20]SANER FH, NOWAK K, HOYER D, et al.A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients[J].BMC Gastroenterol, 2014, 14:4.

[21]BACKHED F, DING H, WANG T, et al.The gut microbiota as an environmental factor that regulates fat storage[J].Proc Natl Acad Sci U S A, 2004, 101 (44) :15718-15723.

[22]PINGITORE A, CHAMBERS ES, HILL T, et al.The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro[J].Diabetes Obes Metab, 2017, 19 (2) :257-265.

[23]FURUSAWA Y, OBATA Y, FUKUDA S, et al.Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells[J].Nature, 2013, 504 (7480) :446-450.

[24]TURNBAUGH PJ, LEY RE, MAHOWALD MA, et al.An obesity-associated gut microbiome with increased capacity for energy harvest[J].Nature, 2006, 444 (7122) :1027-1031.

[25]SCHWIERTZ A, TARAS D, SCHAFER K, et al.Microbiota and SCFA in lean and overweight healthy subjects[J].Obesity (Silver Spring) , 2010, 18 (1) :190-195.

[26]MOUZAKI M, COMELLI EM, ARENDT BM, et al.Intestinal microbiota in patients with nonalcoholic fatty liver disease[J].Hepatology, 2013, 58 (1) :120-127.

[27]JUMPERTZ R, LE DS, TURNBAUGH PJ, et al.Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans[J].Am J Clin Nutr, 2011, 94 (1) :58-65.

[28]MUSSO G, GAMBINO R, CASSADER M.Obesity, diabetes, and gut microbiota:the hygiene hypothesis expanded?[J].Diabetes Care, 2010, 33 (10) :2277-2284.

[29]ULVEN T.Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets[J].Front Endocrinol (Lausanne) , 2012, 3:111.

[30]den BESTEN G, van EUNEN K, GROEN AK, et al.The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism[J].J Lipid Res, 2013, 54 (9) :2325-2340.

[31]den BESTEN G, BLEEKER A, GERDING A, et al.Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation[J].Diabetes, 2015, 64 (7) :2398-2408.

[32]HEBBARD L, GEORGE J.Animal models of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol, 2011, 8 (1) :35-44.

[33]SCHNABL B, BRENNER DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology, 2014, 146 (6) :1513-1524.

[34]ZHU W, GREGORY JC, ORG E, et al.Gut Microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J].Cell, 2016, 165 (1) :111-124.

[35]SINN DH, KANG D, CHANG Y, et al.Non-alcoholic fatty liver disease and progression of coronary artery calcium score:a retrospective cohort study[J].Gut, 2017, 66 (2) :323-329.

[36]SPENCER MD, HAMP TJ, REID RW, et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency[J].Gastroenterology, 2011, 140 (3) :976-986.

[37]SWANN JR, WANT EJ, GEIER FM, et al.Systemic gut microbial modulation of bile acid metabolism in host tissue compartments[J].Proc Natl Acad Sci U S A, 2011, 15 (Suppl 1) :4523-4530.

[38]SCHAAP FG, TRAUNER M, JANSEN PL.Bile acid receptors as targets for drug development[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (1) :55-67.

[39]SAYIN SI, WAHLSTROM A, FELIN J, et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist[J].Cell Metab, 2013, 17 (2) :225-235.

[40]PRAWITT J, ABDELKARIM M, STROEVE JH, et al.Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity[J].Diabetes, 2011, 60 (7) :1861-1871.

[41]INAGAKI T, CHOI M, MOSCHETTA A, et al.Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis[J].Cell Metab, 2005, 2 (4) :217-225.

[42] FANG S, SUH JM, REILLY SM, et al.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J].Nat Med, 2015, 21 (2) :159-165.

[43]THOMAS C, GIOIELLO A, NORIEGA L, et al.TGR5-mediated bile acid sensing controls glucose homeostasis[J].Cell Metab, 2009, 10 (3) :167-177.

[44]ZHU L, BAKER SS, GILL C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:a connection between endogenous alcohol and NASH[J].Hepatology, 2013, 57 (2) :601-609.

[45]PARLESAK A, SCHAFER C, SCHUTZ T, et al.Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease[J].J Hepatol, 2000, 32 (5) :742-747.

[46]ENGSTLER AJ, AUMILLER T, DEGEN C, et al.Insulin resistance alters hepatic ethanol metabolism:studies in mice and children with non-alcoholic fatty liver disease[J].Gut, 2016, 65 (9) :1564-1571.

[47]RAHMAN K, DESAI C, IYER SS, et al.Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol[J].Gastroenterology, 2016, 151 (4) :733-746.e712.

[48]MIELE L, VALENZA V, la TORRE G, et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology, 2009, 49 (6) :1877-1887.

[49]CANI PD, AMAR J, IGLESIAS MA, et al.Metabolic endotoxemia initiates obesity and insulin resistance[J].Diabetes, 2007, 56 (7) :1761-1772.

[50]CANI PD, BIBILONI R, KNAUF C, et al.Changes in gut microbiota control metabolic endotoxemia-induced inflammation in highfat diet-induced obesity and diabetes in mice[J].Diabetes, 2008, 57 (6) :1470-1481.

[51]MENCIN A, KLUWE J, SCHWABE RF.Toll-like receptors as targets in chronic liver diseases[J].Gut, 2009, 58 (5) :704-720.

[52]MIURA K, KODAMA Y, INOKUCHI S, et al.Toll-like receptor 9promotes steatohepatitis by induction of interleukin-1beta in mice[J].Gastroenterology, 2010, 139 (1) :323-334.e327.

[53]MIURA K, YANG L, van ROOIJEN N, et al.Toll-like receptor 2and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice[J].Hepatology, 2013, 57 (2) :577-589.

[54]VIJAY-KUMAR M, AITKEN JD, CARVALHO FA, et al.Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor5[J].Science, 2010, 328 (5975) :228-231.

[55]WREE A, EGUCHI A, MCGEOUGH MD, et al.NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice[J].Hepatology, 2014, 59 (3) :898-910.

[56]VANDANMAGSAR B, YOUM YH, RAVUSSIN A, et al.The NLRP3inflammasome instigates obesity-induced inflammation and insulin resistance[J].Nat Med, 2011, 17 (2) :179-188.

[57]WEN H, GRIS D, LEI Y, et al.Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J].Nat Immunol, 2011, 12 (5) :408-415.

[58]WLODARSKA M, THAISS CA, NOWARSKI R, et al.NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion[J].Cell, 2014, 156 (5) :1045-1059.

[59]HENAO-MEJIA J, ELINAV E, JIN C, et al.Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity[J].Nature, 2012, 482 (7384) :179-185.

施引文献

资源附件(0)

访问统计